Literature DB >> 18695456

Health care expenditures in ulcerative colitis: the perspective of a self-insured employer.

Eric Hillson1, Sharon Dybicz, Heidi C Waters, Bruce Stuart, Justin Schaneman, Omar Dabbous, W Gary Erwin, Andrew Kersh, Delma Broussard.   

Abstract

OBJECTIVE: This study was designed to investigate the incidence, prevalence, treatment patterns, disease severity, and direct costs associated with ulcerative colitis (UC) for claimants in health plans offered by a large self-insured employer in the United States.
METHODS: Retrospective analysis of medical claims with and without UC identified from a population of approximately 500,000 employees, retirees, and dependents.
RESULTS: Costs for UC claimants were more than twice those for the comparator group ($14,486 vs $6158; P < 0.005). Total health care costs for the severe disease cohort were double those of the mild or moderate cohorts ($26,875 vs $12,154 and $12,731), as were inpatient costs ($13,516 vs $3235 and $2244). The annual incremental cost of treating severe disease was $6812 (P < 0.005) compared with mild UC.
CONCLUSION: UC is a significant predictor of increased medical costs with severe disease, driven mainly by inpatient costs.

Entities:  

Mesh:

Year:  2008        PMID: 18695456     DOI: 10.1097/JOM.0b013e31816fd663

Source DB:  PubMed          Journal:  J Occup Environ Med        ISSN: 1076-2752            Impact factor:   2.162


  6 in total

1.  Health care costs and their predictors of inflammatory bowel diseases in Germany.

Authors:  Anne Prenzler; Bernd Bokemeyer; J-Matthias von der Schulenburg; Thomas Mittendorf
Journal:  Eur J Health Econ       Date:  2010-10-22

2.  Telephone Encounters Predict Future High Financial Expenditures in Inflammatory Bowel Disease Patients: A 3-Year Prospective Observational Study.

Authors:  Benjamin Click; Alyce M Anderson; Claudia Ramos Rivers; Ioannis E Koutroubakis; Jana G Hashash; Michael A Dunn; Marc Schwartz; Jason Swoger; Arthur Barrie; Eva Szigethy; Miguel Regueiro; Robert E Schoen; David G Binion
Journal:  J Clin Gastroenterol       Date:  2018-04       Impact factor: 3.062

3.  Demographic and Clinical Predictors of High Healthcare Use in Patients with Inflammatory Bowel Disease.

Authors:  Benjamin Click; Claudia Ramos Rivers; Ioannis E Koutroubakis; Dmitriy Babichenko; Alyce M Anderson; Jana G Hashash; Michael A Dunn; Marc Schwartz; Jason Swoger; Leonard Baidoo; Arthur Barrie; Miguel Regueiro; David G Binion
Journal:  Inflamm Bowel Dis       Date:  2016-06       Impact factor: 5.325

4.  Direct health care insurer and out-of-pocket expenditures of inflammatory bowel disease: evidence from a US national survey.

Authors:  Candace Gunnarsson; Jie Chen; John A Rizzo; Joseph A Ladapo; Jennifer H Lofland
Journal:  Dig Dis Sci       Date:  2012-07-12       Impact factor: 3.199

5.  Group-Based Trajectory Modeling of Healthcare Financial Charges in Inflammatory Bowel Disease: A Comprehensive Phenotype.

Authors:  Jianfei Jiang; Benjamin Click; Alyce M Anderson; Ioannis E Koutroubakis; Claudia Ramos Rivers; Jana G Hashash; Michael A Dunn; Marc Schwartz; Jason Swoger; Arthur Barrie; Miguel Regueiro; Chung-Chou H Chang; David G Binion
Journal:  Clin Transl Gastroenterol       Date:  2016-07-14       Impact factor: 4.488

6.  Indirect costs associated with ulcerative colitis: a systematic literature review of real-world data.

Authors:  Joelle Constantin; Petar Atanasov; Daniel Wirth; Andras Borsi
Journal:  BMC Gastroenterol       Date:  2019-11-09       Impact factor: 3.067

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.